Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
© Martinez-Raga et al; licensee Springer. 2012
Received: 10 January 2012
Accepted: 29 March 2012
Published: 29 March 2012
Opioid addiction is a worldwide problem. Agonist opioid treatment (AOT) is the most widespread and frequent pharmacotherapeutic approach. Methadone has been the most widely used AOT, but buprenorphine, a partial μ-opiod agonist and a κ-opiod antagonist, is fast gaining acceptance. The objective was to assess the budgetary impact in Spain of the introduction of buprenorphine-naloxone (B/N) combination.
A budgetary impact model was developed to estimate healthcare costs of the addition of B/N combination to the therapeutic arsenal for treating opioid dependent patients, during a 3-year period under the National Health System perspective. Inputs for the model were obtained from the specialized scientific literature. Detailed information concerning resource consumption (drug cost, logistics, dispensing, medical, psychiatry and pharmacy supervision, counselling and laboratory test) was obtained from a local expert panel. Costs are expressed in euros (€, 2010).
The number of patients estimated to be prescribed B/N combination was 2,334; 2,993 and 3,589 in the first, second and third year respectively. Total budget is €85,766,129; €79,855,471 and €79,137,502 in the first, second and third year for the scenario without B/N combination. With B/N combination the total budget would be €86,589,210; €80,398,259 and €79,708,964 in the first, second and third year of the analyses. Incremental cost/patient comparing the addition of the B/N combination to the scenario only with methadone is €10.58; €6.98 and €7.34 in the first, second and third year respectively.
Addition of B/N combination would imply a maximum incremental yearly cost of €10.58 per patient compared to scenario only with methadone and would provide additional benefits.
Opioid abuse remains a serious public health problem worldwide, notably in Asia and Europe. Worldwide prevalence of opioid use has been estimated at 0.4% . In Spain, the most recent available data indicated that 0.8% of the population aged 15-64 used opioids in 2007 . Opioid addiction is associated with great economic burden , as well as various and severe health problems, including an increased risk for HIV/AIDS and viral hepatitis B and C infection, generally as a consequence of intravenous drug use. Mortality rates are high as well, particularly among individuals 15-34 years of age . Mortality in dependent heroin users is between 6 and 20 times that expected for the general population of the same age and gender. As a consequence, in many countries, opioid use constitutes the main cause of drug-related deaths .
Pharmacological interventions for heroin dependence aim primarily at maximizing treatment retention, attaining long-term abstinence and minimizing the risk of returning to the previous pattern of drug abuse following safe and efficient suppression of opioid withdrawal symptoms [5, 6]. Different types of medications are used in the management of opioid dependent patients, including opioid agonists and partial agonists, opioid antagonists and alpha (2)-adrenergic agonists [6–8]. Agonist opioid treatment (AOT) is the most common intervention for heroin dependence . Methadone, as part of an AOT program, is the most widely used and well researched pharmacotherapy for heroin dependent patients since the 1960s . However, other agonists alone or in combination with antagonist compounds are increasingly used .
Buprenorphine, a partial μ-opiod receptor agonist and a κ-opiod receptor antagonist, is fast gaining acceptance among addiction specialists and patients [10–12], partly due to methadone, as the sole available AOT in most countries fails to meet the specific treatment needs of all opioid-dependent individuals who might benefit from medication. This may help to explain why a significant proportion of these patients remain untreated . Solid evidence has shown the efficacy of buprenorphine for treating heroin addiction [8, 14–16]. A buprenorphine/naloxone (B/N) combination (Suboxone®, Reckitt Beckinser Pharmaceuticals Limited) was approved by the European Medicines Agency (EMA) in September 2006 as oral substitution treatment for opioid drug dependence within a framework of medical, social and psychological treatment . The rationale for developing a new compound, combining naloxone with buprenorphine was to minimize the risk of intravenous misuse. Injection of naloxone would precipitate opioid withdrawal in opioid-dependent patients, but taken sublingually, as prescribed, the bioavailability of naloxone is negligible, therefore allowing for the patient to benefit from effects of buprenorphine alone [18, 19]. As a result of the reduced risk for diversion and misuse there is less need for direct close supervision of medication during OST, less resources involved therefore allowing for a reduction in associated costs and for treatment to become more accessible . In addition, there is evidence that buprenorphine/naloxone is an effective and well-tolerated treatment for medically assisted opioid withdrawal when the dosage is titrated to achieve good control of withdrawal symptoms [21, 22].
Additionally to the primary outcomes on efficacy/effectiveness and safety, the results provided in economic evaluations (cost-effectiveness and budgetary impact) could be a crucial source to be used by health care provider for the purpose of decision making . Budgetary impact studies are a direct tool for helping decision makers to perform a better allocation of available resources, mainly in the present global situation of cost constraint we are living.
The aim of this study was to assess the budgetary impact in Spain of buprenorphine-naloxone (B/N) combination (Suboxone®) as a newly approved pharmacotherapy for opioid dependence, specifically compared to methadone the only widely available medication for heroin addiction.
Eligible population was obtained from estimates of National Program on Drugs . Approval of B/N have not increased the total annual population in AOT, consequently the number of patients remained unchanged throughout the simulation.
Patients needing medically assisted withdrawal (MAW) program prior to entering a relapse prevention program, therefore not in AOT.
Patients in high threshold programs (HTP). These included those individuals without any physical or psychological impairment, and despite showing good adherence to AOT have difficulties in staying abstinent. These patients require high levels of supervision.
Patients in low-intermediate threshold program (LITP) were those with some physical and/or psychological impairment and poor adherence to AOT. These patients have less supervision and more commonly are poly-substances abusers.
In the base case of the model, the first year of the simulation begins with no patients on MAW stage. According the expert panel opinion, in the first year 30.0% of patients are HTP and 70.0% are LITP.
Two pharmacotherapies were considered in the analysis: methadone and B/N combination. Although the opioid antagonist naltrexone was also available as a treatment option for relapse prevention for heroin dependent subjects, this medication was excluded from the analysis due its limited acceptance among both patients and clinicians  and the lack of sufficient evidence supporting its use as a maintenance therapy for opioid dependence .
An expected 10.0%, 15.0% and 20.0% of patients entering B/N combination were considered in the model in the first second and third year, respectively, in the HTP group. It was assumed that all patients in LITP would remain on methadone treatment. Two scenarios were compared in the analysis: a situation with 100.0% of patients in AOT treated with methadone versus an alternative option considering annual gradual increases of patients entering B/N combination.
Time horizon, perspective and discounting
The analysis was performed with a 3-year time projection with 3 cycles of 1 year each within the context of the National Health System. However, considering that in Spain addiction treatment programs and services are organized and developed by Autonomous Regional Governments, results are shown by Autonomous Regions, as well.
As stated in the good practices of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) , budget impact analyses present financial streams over time, and it is not necessary to discount the costs.
Resources and costs
Drug costs: Pharmacological costs of the pharmacotherapies evaluated that were calculated based on defined daily dose as established by the World Health Organization  and expert panel opinion. An average daily dose of 8 mg per patient was considered for B/N combination, and of 60 mg for methadone (independently of whether patients were HTP or LITP).
Logistic costs: Distribution and production resources were considered. These included a series of procedures generally performed by an accredited pharmacist such as collecting and storing methadone with adequate safety measures, transporting the methadone to central pharmacies for individual methadone hydrochloride dose preparation, subsequent distribution to the dispensing centres, and finally collection of unused doses. An average of four minutes per methadone dose for distribution and 2 minutes per methadone dose for production were considered for the purpose of cost estimation. No logistics resources were involved in B/N combination.
Dispensing: Five minutes of nursing staff for dispensing methadone to patients was considered in the analysis. Methadone dispensing twice a week was taken into account in HTP patients for the first year (104 dispensations) and once a week for the second and third year (52 dispensations per year). Once a week dispensing was considered for LITP patients. No dispensing was required in the case of B/N combination treatment. In addition, it was assumed that 36 dispensation (associated with non-AOT drugs) per year are needed in MAW patients.
Medical, psychiatry and pharmacy staff involvement: Medical supervision (15 minutes) is required for patients in AOT. Ten visits by year in MAW and HTP patients and 6 visits by year in LITP. For psychiatric care 10 sessions (25 minutes/session) were assumed in MAW and first year of treatment in HTP. Ten sessions by year was also assumed for 2nd and 3rd year in HTP methadone treated patients. Five sessions by year for 2nd and 3rd year in patients treated with B/N combination. No psychiatric care for LITP patients was included. Pharmacy supervision (1 minute) is estimated to be done 36 times by year in MAW patients, and daily in HTP and LITP.
Counselling: Twenty-five minutes sessions with specialist addiction of psychologist were also included in the analysis. A total of 20 sessions/year for MAW and first year of treatment for HTP patients was assumed, whilst for each of the second and third year the number of estimated sessions was 10 for methadone treated patients and 5 for patients treated with B/N combination. In addition, the assumption was made that LITP patients would not be involved in specialist psychological counselling. Social and employment rehabilitation care (15 minutes per session) provided by social workers to individuals in AOT was also taken into account. (See Table 2 for detailed social worker assistance)
Methadone 1 st year
Methadone 2 nd & 3 rd year
B/N 1 st year
B/N 2 nd & 3 rd year
Monitoring (analytical controls)
Laboratory test: Urine toxicology drug screenings were also included in the analysis.
Unitary costs (€, 2010)
Cost (€, 2010)
531.80 € per methadone kg
Buprenorphine/Naloxone combination (Suboxone®, 8/2 mg, 7 tablets)
2.37€ per tablet
Monitoring (analytical controls)
Transition probabilities: The same values applied for methadone were also assumed for B/N combination.
Patients commencing B/N combination: In Spain there is only an Autonomous Region (Murcia) where B/N combination is fully financed by the Regional Health Care System with a free access to the drug. A sensitivity analysis with the proportion of patients starting B/N combination treatment over the previous three years available for this region was performed (0.97%, 2.57% and 3.83%) 
Initial distribution of patients: Influence of 100% of patients in LITP or 100% of patients in HTP was tested.
Resource costs: Differences of ± 10% in cost per minute of resources were tested.
Treatment population: patients on AOT programs
According to National Health estimates of the Spanish National Program on Drugs , a total of 77,811 patients were calculated to be enrolled in AOT.
According to patient distribution within each target group and the projection of the percentage of specific AOT medication use over the three years of the study period, the number of patients expected to be treated with B/N combination during the first, second and third year of the study was 2,334; 2,993 and 3,589, respectively. The simulation in the defined base case begins with 30.0% of the total population in HTP. In the scenario without B/N combination, a total of 1,167 patients progressed to MAW in the 2nd year and 1,595 in 3rd year. Addition of B/N combination was associated with 1,466 and 2,114 MAW patients in the first and second year.
Budgetary impact results (€, 2010)
Scenario without B/N combination
Scenario with B/N combination
Difference (€) with B/N vs. without B/N
2 nd year
3 rd year
Results by Autonomous Region
Scenario without B/N combination Budget impact (€)
Scenario with B/N combination Budget impact (€)
Difference (€) with B/N vs. without B/N
Castilla La Mancha
Results of one-way sensitivity analyses.
Value in BC
Value in SA
Scenario without B/N combination
Scenario with B/N combination
Difference (€) with B/N vs. without B/N
1 st year
2 nd year
3 rd year
1 st year
2 nd year
3 rd year
1 st year
2 nd year
3 rd year
See table 1
Same values for B/N combination than used for methadone
B/N combination uptakes
10%, 15% and 20% for 1st, 2nd and 3rd year
0.97%; 2.57% and 3.83% for 1st, 2nd and 3rd year
Initial proportion of patient distribution
HTP: 30% and LITP: 70%
Resource cost (cost per minute)
See table 3
When the number of patients commencing B/N combination from the Murcia Region is applied to national level the incremental total budgetary impact of AOT in the scenario with B/N combination versus scenario without B/N combination was €79.839, €106,513 and €122,872 for the first, second and third year. Differences in cost per patient between the 2 scenarios are €1.03, €1.37 and €1.58 for each of the three years.
The results from the present study show that approval of a novel medication for heroin dependent patients, namely B/N combination compared to the only AOT available, methadone, is associated with increases in direct pharmacological costs, but it is also directly associated with reduction of other type of costs involved, as analysed, including logistics/distribution, production, delivery, supervision and monitoring.
According to the results of the sensitivity analysis, the parameters with the most influence on the final outcomes would be those associated with patient profile and percentage of B/N combination use. The number of patients commencing B/N combination each year, used in the sensitivity analysis, was obtained from a market sales database , representing real use of B/N combination in a specific region in Spain (Murcia). Base case is a conservative approach to the approval of B/N combination, as intake values used are higher than real life values. If market conditions of Murcia are extrapolated to national level the total budgetary impact per patient would be €1.03, €1.37 and €1.58 for the first, second and third year of the analysis.
These results are in concordance with those obtained in the previous publication of the original model . The present work is an update as much the current situation in terms of number of patients as costs. Besides, this paper provides more details of the resource consumption and more accurate estimates of the budgetary impact, based on data following the real use of B/N combination.
The model developed for the analysis aims to be a transparent tool. All the parameters included and assumptions considered are presented in such a detailed manner to allow for replication in similar or different settings. Third payer perspective was chosen to provide useful data for the decision makers at the funding administration level.
There are several limitations to be considered in this model, including the very limited number of published reports regarding resource consumption in population in AOT, and as a consequence analysis relied on expert panel estimations. Pragmatic or naturalistic prospective studies conducted under standard clinical practice, designed to collect resources and costs data associated to AOT could provide reliable information to be used in further economic evaluations . A potential limitation of the model refers to the assumption that approval of B/N combination would not cause a significant elevation of the population entering AOT. An increase in the number of patients entering in AOT was reported in the UK when buprenorphine was licensed in the UK in 1999 , but early experiences in Spain following with the approval of B/N combination does not suggest that this could be expected [24, 30]. Therefore to avoid confounding factors on the final results, it was decided to keep a constant value for population under AOT. Potential improvements in quality of life and benefits resulting from better integration at a social level were not included in the present model, but there is evidence that buprenorphine is associated to better results at psychological, medical, family and work level than other treatments . A conservative approach has been chosen for some aspects. Frequency of urine drug testing remained unchanged with B/N combination, however it would be expected a decrease in number of toxicological screenings, with a subsequent reduction in associated costs .
There is the common perception that methadone may be more effective than buprenorphine for as an AOT, primarily based on studies and experiences with low buprenorphine doses and excessively slow induction regimens as used in early buprenorphine trials [11, 41]. However subsequent studies showed that the efficacy of buprenorphine sublingual tablet or buprenorphine/naloxone sublingual tablet (Suboxone®) is equivalent to that of methadone when sufficient buprenorphine doses, rapid induction, and flexible dosing are used [22, 42, 43]. Effectiveness has been also tested concluding that buprenorphine is at least as effective as methadone and has a better tolerability profile in reducing illicit opioid when use in clinical practice [8, 12, 44]. Published evidence have suggested that assuming that B/N combination is not more or less effective than methadone but it will be less expensive in the long run, it is expected that B/N combination would be more cost-effective than methadone when provided to comparable groups of patients . Although methadone will remain an essential relapse prevention pharmacotherapy for opioid addicted individuals, buprenorphine-based regimens may increase access to care and provide safer, more appropriate treatment than methadone for some patients [11, 44]. In addition buprenorphine is an alternative treatment for heroin dependent patients, especially for those who do not wish to start or continue with methadone or for those who do not seem to benefit from adequate dosages of methadone .
The budget impact analyses are important, along with the cost-effectiveness analysis, as part of a comprehensive economic evaluation of a new health technology . The purpose of a budget impact study is to estimate the financial consequences of adoption and diffusion of a new health-care intervention within a specific health-care setting or system context given inevitable resource constraints . In Spain there are no official threshold values published for health technologies implementation. According to authors' criteria, the increases in total cost of AOT with B/N combination's incorporation obtained in this study seem reasonable, even more if additional benefits at clinical level for patients are considered.
The introduction of new (and expensive) pharmaceutical products is one of the major challenges for health systems . New treatments, procedures and technologies into the services' portfolio of healthcare providers should aim to improve three areas equally: patient access to innovative solutions, the sustainability of the health system and compensation for innovation. Traditional schemes based on fixed prices that fail to consider the product's appropriate use or its results in terms of effectiveness may lead to inefficient decision-making processes . Risk-sharing agreements are defined as a new form of contractual agreement between payers and the pharmaceutical industry for setting the value of an innovation conditional to demonstration of its effectiveness and efficiency in real life . This type of agreements could be taken in mind when health authorities face a regulatory decision on drug pricing and reimbursement in a context of uncertainty , as they could diminish the impact on the payer's budget for new and existing medicines brought about by either the uncertainty of the value of the medicine and/or the need to work within finite budgets .
Addition of B/N combination would imply a maximum incremental yearly cost of €10.58 per patient compared to scenario only with methadone and would provide additional benefits
The results of this report would help the Regional and National Authorities to perform a better allocation of available resources associated to addiction treatment services.
- United Nations Office on Drugs and Crime: UNODC. World Drug Report 2010 (United Nations Publication, Sales No. E.10.XI.13) [http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf]
- Ministerio de Sanidad, Politica Social e Igualdad: National Program on Drugs (Plan Nacional sobre drogas) Observatorio Español sobre Drogas. Informe 2009 [http://www.pnsd.mspsi.es/Categoria2/observa/pdf/oed-2009.pdf]
- Mark TL, Woody GE, Juday T, Kleber HD: The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001, 61: 195–206. 10.1016/S0376-8716(00)00162-9PubMedView ArticleGoogle Scholar
- Hall W, Darke S: Trends in opiate overdose deaths in Australia 1979–1995. Drug Alcohol Depend 1998, 52: 71–77. 10.1016/S0376-8716(98)00044-1PubMedView ArticleGoogle Scholar
- Gonzalez G, Oliveto A, Kosten TR: Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 2004, 5: 713–725. 10.1517/146565188.8.131.523PubMedView ArticleGoogle Scholar
- Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ: A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010, 30: 155–166. 10.1016/j.cpr.2009.10.006PubMedView ArticleGoogle Scholar
- Gowing L, Farrell M, Ali R, White JM: Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2009, (2):CD002024.Google Scholar
- Soyka M, Kranzler HR, van den Brink W, Krystal J, Möller HJ, Kasper S, WFSBP Task Force on Treatment, Guidelines for Substance Use Disorders: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry 2011, 12: 160–187. 10.3109/15622975.2011.561872PubMedView ArticleGoogle Scholar
- Uchtenhagen A: Substitution management in opioid dependence. J Neural Transm Suppl 2003, 66: 33–60.PubMedGoogle Scholar
- George S, Day E: Buprenorphine in the treatment of opioid dependence. Br J Hosp Med (Lond) 2007, 68: 594–597.View ArticleGoogle Scholar
- Maremmani I, Gerra G: Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010, 19: 557–568. 10.1111/j.1521-0391.2010.00086.xPubMedView ArticleGoogle Scholar
- Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S: Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004, 75: 37–45. 10.1016/j.drugalcdep.2003.11.017PubMedView ArticleGoogle Scholar
- Ling W, Rawson RA, Compton MA: Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs 1994, 26: 119–128. 10.1080/02791072.1994.10472259PubMedView ArticleGoogle Scholar
- Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D: Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998, 93: 475–486. 10.1046/j.1360-0443.1998.9344753.xPubMedView ArticleGoogle Scholar
- Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE: A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995, 40: 17–25. 10.1016/0376-8716(95)01186-2PubMedView ArticleGoogle Scholar
- Kakko J, Svanborg KD, Kreek MJ, Heilig M: 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003, 361: 662–668. 10.1016/S0140-6736(03)12600-1PubMedView ArticleGoogle Scholar
- European Medicines Agency: Summary of Products Characteristics (Suboxone). [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000697/WC500058505.pdf]
- Johnson RE, Strain EC, Amass L: Buprenorphine: how to use it right. Drug Alcohol Depend 2003,70(2 Suppl):S59–77.PubMedView ArticleGoogle Scholar
- Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D: Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphinenaloxone. N Engl J Med 2003, 349: 949–958. 10.1056/NEJMoa022164PubMedView ArticleGoogle Scholar
- Doran CM: Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2005, 5: 583–591. 10.1586/14737184.108.40.2063PubMedView ArticleGoogle Scholar
- Horspool MJ, Seivewright N, Armitage CJ, Mathers N: Post-treatment outcomes of buprenorphine detoxification in community settings: a systematic review. Eur Addict Res 2008, 14: 179–185. 10.1159/000141641PubMedView ArticleGoogle Scholar
- Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG: Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Clin Drug Investig 2010,30(Suppl 1):21–26.PubMedView ArticleGoogle Scholar
- Niezen MG, de Bont A, Busschbach JJ, Cohen JP, Stolk EA: Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care 2009, 25: 49–55. 10.1017/S0266462309090072PubMedView ArticleGoogle Scholar
- Martínez-Raga J, González Saiz F, Pascual C, Casado MA, Sabater Torres FJ: Suboxone (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis. Eur Addict Res 2010, 16: 31–42. 10.1159/000259614PubMedView ArticleGoogle Scholar
- Brosa M, Gisbert R, Rodríguez JM, Soto J: Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario. PharmacoEconomics Span Res Art 2005, 2: 64–78.Google Scholar
- Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007, 10: 336–347. 10.1111/j.1524-4733.2007.00187.xPubMedView ArticleGoogle Scholar
- Orlewska E, Mierzejewski P: Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004, 7: 1–10. 10.1111/j.1524-4733.2004.71257.xPubMedView ArticleGoogle Scholar
- Trueman P, Drummond M, Hutton J: Developing guidance for budget impact analysis. Pharmacoeconomics 2001, 19: 855–867. 10.2165/00019053-200119080-00007View ArticleGoogle Scholar
- Lilford R, Royston G: Decision analysis in the selection, design and application of clinical and health services research. J Health Serv Res Policy 1998, 3: 159–166.PubMedGoogle Scholar
- Ministerio de Sanidad, Política Social e Igualdad: National Program on Drugs (Plan Nacional sobre drogas) Memoria 2009 [http://www.pnsd.msc.es/Categoria2/publica/pdf/memo2009.pdf]
- Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV: Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007, 91: 289–292. 10.1016/j.drugalcdep.2007.06.013PubMed CentralPubMedView ArticleGoogle Scholar
- Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A: Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011, 4: CD001333.PubMedGoogle Scholar
- World Health Organization: Collaboration centre for drugs statistics methodology. [http://www.whocc.no/atc_ddd_index/?code=N07BC51]
- National Statistics Institute: Instituto Nacional de Estadística. Indice de precios al consumo. [http://www.ine.es/calcula/index.do?L=0]
- Royal Decree-Law [Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. BOE de 24 de mayo de 2010:126] [http://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010–8228.pdf]
- IMS Health. MIDAS, MAT. [database] 2010.Google Scholar
- Sacristan JA, Galende I, Soto J: Estudios naturalísticos para valorar la efectividad de los medicamentos tras su comercialización: ¿por qué, cuándo y cómo? Aten Primaria 1998, 22: 182–185.PubMedGoogle Scholar
- de Wet CJ, Reed LJ, Bearn J: The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001–03. Addiction 2005, 100: 495–499. 10.1111/j.1360-0443.2005.01039.xPubMedView ArticleGoogle Scholar
- Raisch DW, Campbell HM, Garnand DA, Jones MA, Sather MR, Naik R, Ling W: Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. Qual Life Res 2011, in press.Google Scholar
- Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S: Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007, 5: 146–150. 10.1370/afm.665PubMed CentralPubMedView ArticleGoogle Scholar
- Ling W, Wesson DR, Charuvastra C, Klett CJ: A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996, 53: 401–407. 10.1001/archpsyc.1996.01830050035005PubMedView ArticleGoogle Scholar
- Petitjean S, Stohler R, Déglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D: Double-blind randomized trial of buprenorphine and methadone in opiatedependence. Drug Alcohol Depend 2001, 62: 97–104. 10.1016/S0376-8716(00)00163-0PubMedView ArticleGoogle Scholar
- Johnson RE, Jaffe JH, Fudala PJ: A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267: 2750–2755. 10.1001/jama.1992.03480200058024PubMedView ArticleGoogle Scholar
- Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA: Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med 2011, 5: 254–263. 10.1097/ADM.0b013e3182312983PubMedView ArticleGoogle Scholar
- Rosenheck R, Kosten T: Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001, 63: 253–262. 10.1016/S0376-8716(00)00214-3PubMedView ArticleGoogle Scholar
- Davids E, Gastpar M: Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 2004, 14: 209–216. 10.1016/S0924-977X(03)00146-9PubMedView ArticleGoogle Scholar
- Barros PP: The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ 2011, 20: 461–470. 10.1002/hec.1603PubMedView ArticleGoogle Scholar
- Espín J, Oliva J, Rodríguez-Barrios JM: Innovative patient access schemes for the adoption of new technology: risk-sharing agreements. Gac Sanit 2010, 24: 491–497. 10.1016/j.gaceta.2010.07.011PubMedView ArticleGoogle Scholar
- de Pouvourville G: Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 2006, 7: 155–157. 10.1007/s10198-006-0386-6PubMedView ArticleGoogle Scholar
- Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R: Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law 2011, 6: 391–403. 10.1017/S1744133111000016PubMedView ArticleGoogle Scholar
- Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL: Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010, 10: 153. 10.1186/1472-6963-10-153PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.